Skip to main content
Premium Trial:

Request an Annual Quote

Opko Licenses Protein Biomarker Panel for Prostate Cancer to IHT

NEW YORK (GenomeWeb News) – Opko Health today announced it has granted UK-based International Health Technology the rights to offer a novel panel of protein biomarkers and an associated algorithm in parts of Europe for the detection of prostate cancer.

Under the terms of the deal, IHT will offer the biomarker panel in laboratory settings in the UK, Ireland, Sweden, and Denmark. Financial and other terms were not disclosed.

The deal covers a panel of kallikrein biomarkers, which Opko said studies have shown to be able to eliminate more than half of unnecessary prostate biopsies. Opko had licensed two kallikrein biomarkers from Finnish biotech Arctic Partners, GenomeWeb Daily News' sister publication ProteoMonitor reported earlier this year.

Phillip Frost, Chairman and CEO of Opko, said in a statement, "We believe this technology will enable IHT to provide the patients they serve with better and more efficient healthcare, while lowering overall costs. We hope eventually that this panel will become the standard of care in prostate cancer screening."

Opko, based in Miami, is a multinational biopharmaceutical and diagnostics firm. IHT helps companies commercialize products.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.